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Abstract: Atopic dermatitis (AD) is a common
inflammatory skin disease characterized by
intensely pruritic lesions. The prevalence of
atopic dermatitis is increasing in developing
regions, including Africa and the Middle East.
However, these regions are underrepresented in
the dermatology literature, and a better under-
standing of the growing burden of atopic der-
matitis in Africa and the Middle East is
necessary. Herein, we summarize current
knowledge on atopic dermatitis epidemiology,
disease burden, and treatment options in Africa
and the Middle East, highlighting the unmet
needs of patients in these regions. With these
needs in mind, we provide clinical recommen-
dations for appropriate management of atopic
dermatitis in Africa and the Middle East.
Funding: Pfizer Inc.
Plain Language Summary: Plain language
summary available for this article.
Keywords: Africa; Atopic dermatitis; Middle
East; Prevalence; Quality of life; Therapeutics
Mohamed Mounir and Anna M. Tallman: Former Pfizer
employees.
Enhanced digital features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.7668206.
K. A. M. Al-Afif (&)
Al Noor Specialist Hospital, Mecca, Saudi Arabia
e-mail: kh_alafif5@yahoo.com
M. A. Buraik
Department of Dermatology, King Fahd Central
Hospital, Jizan, Saudi Arabia
J. Buddenkotte  M. Steinhoff
Department of Dermatology and HMC Translational
Research Institute, Hamad Medical Corporation,
Doha, Qatar
M. Mounir
Departments of Inflammation and Immunology
and Emerging Markets, Pfizer Inc, Dubai, United
Arab Emirates
R. Gerber
Departments of Outcomes and Evidence and
Statistics, Pfizer Inc, Groton, CT, USA
H. M. Ahmed
Departments of Inflammation and Immunology
and Emerging Markets, Pfizer Inc, Jeddah, Saudi
Arabia
A. M. Tallman
Global Medical Affairs, Pfizer Inc, New York, NY,
USA
M. Steinhoff
Weill Cornell Medicine-Qatar, Doha, Qatar
M. Steinhoff
Qatar University, Doha, Qatar
M. Steinhoff
Department Of Dermatology, Weill Cornell
University, New York, NY, USA
Dermatol Ther (Heidelb) (2019) 9:223–241
https://doi.org/10.1007/s13555-019-0285-2
PLAIN LANGUAGE SUMMARY
This article reviews the epidemiology and dis-
ease burden of atopic dermatitis, an inflamma-
tory skin disease, in Africa and the Middle East,
and outlines appropriate treatment options for
patients in these regions. Defining unmet needs
in atopic dermatitis (AD), analyzing current
treatment options, and exploring factors that
contribute to AD burden in these understudied
regions are important as AD is frequently
encountered and difficult to manage.
INTRODUCTION
Atopic dermatitis (AD) is a common inflamma-
tory skin disease characterized by the develop-
ment of highly pruritic eczematous lesions
[1, 2]. AD often begins in infancy and follows a
chronic, relapsing course [1–3]. Diagnosis is
based on patient and family history, as well as
clinical characteristics of the disease, and is
guided by several sets of diagnostic criteria,
most of which derive from the 1980 Hanifin
and Rajka criteria [3]. A 2003 update of the
Hanifin and Rajka criteria by the American
Academy of Dermatology (AAD) established
essential, important, and associated features of
AD [1, 2]. Essential features include pruritus and
eczematous lesions that can be acute (erythema
and vesicular eruptions), subacute (ill-defined
weepy crusted plaques), or chronic (well-
defined, dry lichenified plaques). Skin lesions
often show age-specific morphology and distri-
bution patterns [2]. Important features include
early onset, dryness, and increased
immunoglobulin E (IgE) level (atopy), although
about 20% of patients with AD do not have
elevated IgE levels [2]. Associated features assist
in diagnosis and can include numerous sec-
ondary signs such as hyperlinear palms and
atypical vascular responses [2]. A diagnosis of
AD requires the exclusion of numerous other
dermatologic conditions (e.g., scabies, sebor-
rheic dermatitis, contact dermatitis, ichthyoses,
cutaneous T cell lymphoma, psoriasis, photo-
sensitivity dermatoses, immunodeficiency dis-
orders, erythroderma of other causes) [2, 4].
Evidence of neuroimmune dysregulation (e.g.,
abnormal levels of interleukin [IL]-31, IL-4, IL-
13, brain-derived natriuretic peptide) may fur-
ther assist in differential diagnosis [5–10].
AD etiology is heterogeneous and complex,
involving genetic, environmental, and neu-
roimmune factors that contribute to skin barrier
dysfunction and inflammation [1]. Family his-
tory of AD is the strongest risk factor for the
condition [1]. Known genetic risk factors include
null mutations in the filaggrin (FLG) gene that
encodes an epidermal structural protein and risk
genes in susceptibility loci related to immune
mechanismsofAD [1, 11]. Environmental factors
such as climate, urban versus rural dwelling, diet,
breastfeeding, obesity, and pollution also con-
tribute to AD risk [12]. Cutaneous inflammation,
a hallmark of AD, is characterized by processes
that include CD4? cell infiltration and elevated
inflammatory cytokines [1]. Recently, neuroim-
mune risk factors including IL-4, IL-13, and IL-31
have been implicated in AD inflammation and
pruritus [5, 6, 8, 13, 14]. IL-31 has also been
shown to promote growth of itch-related sensory
nerves [15].
Guidelines for AD treatment are similar
globally (Table 1) [16–21]. Nonpharmacological
treatment primarily focuses on adequate skin
care, with regular moisturizer and emollient use
recommended to prevent dryness and
transepidermal water loss [16–21]. Other non-
pharmacological treatments include behavioral
interventions [18–20, 22] and stress reduction
and psychological counseling [18, 19, 21, 23].
Common behavioral interventions involve
identification and avoidance of triggers of itch,
such as excessive sweating, wearing of wool
fabrics, and food and environmental allergens
[18–20, 22]. Topical corticosteroids (TCSs)
remain the primary anti-inflammatory treat-
ment option for AD [16, 18–20]. However,
topical calcineurin inhibitors (TCIs) may be
preferable for treatment of sensitive areas (face,
neck, genitals), and they can be used in con-
junction with or in place of TCSs for long-term
use as steroid-sparing therapies [16, 18–20].
Other therapeutic approaches include ultravio-
let therapy and systemic treatments such as
antibiotics and broad immunosuppressants
(e.g., cyclosporine A, azathioprine, methotrex-
ate, mycophenolate mofetil) [17–21]. Recently
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developed anti-inflammatory medications such
as dupilumab injection and crisaborole oint-
ment are thus far approved for treatment of AD
in the USA (dupilumab, crisaborole) [24, 25],
the European Union (dupilumab) [25], Canada
(dupilumab) [26], and Japan (dupilumab) [27].
Crisaborole ointment is a nonsteroidal phos-
phodiesterase 4 inhibitor for the treatment of
mild to moderate AD [28]. Dupilumab is a bio-
logic that targets the IL-4 receptor [24]. While
recommendations for crisaborole are not yet
included in clinical guidelines documents,
dupilumab was recommended in the 2018
European Academy of Dermatology and Ven-
erology (EADV) guidelines update for treatment
of moderate to severe AD in patients whose AD
is inadequately controlled by topical therapies
and for whom other systemic therapy is inad-
visable [21].
AD is highly prevalent in developed coun-
tries, where prevalence rates seem to have pla-
teaued at 10–20% [1]. However, AD prevalence
is increasing in developing countries, including
Africa and the Middle East [29, 30]. Although
AD is becoming a pressing public health con-
cern in Africa and the Middle East, these regions
are underrepresented in the AD literature [31].
Treatment has been hindered by a lack of
regionally appropriate diagnostic and research
tools and by gaps in knowledge and reporting of
AD [31]. An investigation of the nature and
underlying causes of growing burden of AD in
Africa and the Middle East can help address
challenges to medical care in these regions and
inform our understanding of AD. In this review,
we will explore the epidemiology, etiology, and
treatment of AD in the Middle East and Africa
and provide recommendations for addressing
unmet therapeutic needs in these regions.
OBJECTIVE
We aim to (1) provide an overview of the bur-
den of AD in Africa and the Middle East, (2)
outline the unmet need for novel therapeutic
options for AD in this part of the world, and (3)
offer clinical recommendations for improving
the management of atopic disease in Africa and
the Middle East.
METHODS
A literature search was conducted using
PubMed and Web of Science for articles pub-
lished in English within the previous 10 years.
Search terms included ‘‘atopic dermatitis,’’
‘‘Middle East,’’ ‘‘Africa,’’ ‘‘prevalence,’’ and
‘‘treatment.’’ Articles were manually reviewed
for relevance, and additional searches were
conducted to supplement the narrative where
appropriate. Articles referenced throughout the
current review include primary articles, clinical
guidelines documents, and reviews, with pri-
mary articles preferentially referenced where
possible. This article is based on previously
conducted studies and does not contain any
studies with human participants or animals
performed by any of the authors.
PREVALENCE
The prevalence of AD varies significantly
throughout the world [29]. Historically, the
prevalence of AD in Africa and Middle Eastern
countries has generally been lower than in
Europe and North America, but recent time
trends show increasing AD prevalence in the
developing world [1, 31]. The most compre-
hensive global epidemiological data can be
sourced from the International Study of Asthma
and Allergies in Childhood (ISAAC) [32, 33].
Investigators from ISAAC phase 3, which sur-
veyed more than 1 million schoolchildren
throughout the world between 1999 and 2004,
estimated the lifetime prevalence of AD in 6- to
7-year-old children to be relatively low in the
eastern Mediterranean (7.2%) and high in Africa
(23.3%) [32, 33]. The global prevalence for 6- to
7-year-old children was 14.2%. The investiga-
tors from ISAAC phase 3 estimated the lifetime
prevalence of AD in 13- to 14-year-old children
to be moderate in the eastern Mediterranean
(10.8%) and in Africa (15.2%). The global
prevalence for 13- to 14-year-old children was
12.8%. Prevalence differed between and within
countries in the Middle East and Africa.
According to a 2012 systematic review, the
prevalence of AD in Africa was increasing [29].
The lifetime prevalence of AD symptoms in 13-
228 Dermatol Ther (Heidelb) (2019) 9:223–241
to 14-year-old children approximately doubled
in Morocco, South Africa, and Kenya over an
approximate 7-year period (1995–2001/2002).
In contrast, the prevalence of AD symptoms in
13- to 14-year-old Nigerian children decreased
during this period, although this trend may
have been impacted by extremely high baseline
prevalence. The same review did not find a clear
time trend of change in Middle Eastern preva-
lence, citing studies that indicated increasing
(Israel) and decreasing (Kuwait) lifetime preva-
lence. A 2008 comparison of ISAAC phases 1
(1992–1997) and 3 (1999–2004) found large
increases in prevalence (at least two standard
errors [SE]) in 13- to 14-year-old children in
Kenya and Algeria [30]. Of nine African
regions/countries surveyed in both phases,
seven had higher lifetime prevalence in phase 3
than in phase 1 among 13–14 year olds. Of the
six eastern Mediterranean regions/countries
surveyed in both phases, four had higher phase
3 than phase 1 lifetime prevalence in this age
group. All four eastern Mediterranean
regions/countries surveyed for 6–7 year olds
reported higher phase 3 than phase 1 lifetime
prevalence.
Regional and ethnic diversity may play a
significant role in variable rates of prevalence in
the Middle East. For instance, prevalence differs
between countries of Semitic (Qatar, Oman,
Saudi Arabia) and Persian (Iran) origin, and
between urban and rural or desert regions in
Iran [34].
IMPACT OF SOCIAL,
ENVIRONMENTAL,
AND ECONOMIC FACTORS
ON THE BURDEN OF ATOPIC
DERMATITIS
Many environmental, social, and economic
factors relevant to Africa and the Middle East
contribute to increasing prevalence and burden
of AD (Table 2) [12, 19, 35–49]. Dwelling in
urban environments compared with rural envi-
ronments has been linked to AD in both the
Middle East and Africa [34, 37]. In Iran, preva-
lence of AD is higher in Tehran (17.6%) and
Kerman (9.1%) than in Shahr-e-Kord (2.1%), a
western city where a greater proportion of citi-
zens have rural lifestyles [34]. A similar pattern
has been observed in Africa, with higher income
and more urban countries such as South Africa
showing large recent increases in AD prevalence
[50]. Within individual African countries, AD
risk often follows an urban–rural gradient, with
a higher rate of AD in city dwellers than in rural
dwellers [37]. Effects of increased socioeco-
nomic status and urbanization on prevalence of
AD are thought to stem from factors that
include increased air pollution, sedentary life-
style and diet, and smaller family size
[12, 31, 50].
Findings in Africa support the ‘‘hygiene
hypothesis,’’ which argues that increased
prevalence of AD stems, at least in part, from
decreased exposure to infection and microor-
ganisms in early childhood [12]. In rural
Ethiopia, higher rates of AD have been reported
in children with access to piped drinking water
than in children who drink river water, an effect
attributed to reduced exposure to enteric
infections [51]. Helminth (parasitic) infections,
which are highly prevalent in Africa, have been
shown to promote protection from atopic ill-
ness [31]. Results of an analysis of more than
2000 children in Uganda showed that maternal
hookworm infection during pregnancy and
early childhood infection with Trichuris trichiura
or hookworm both were negatively associated
with AD [37]. Protection may be mediated by
regulatory T and B cells, parasite-induced
expression of the anti-inflammatory cytokine
IL-10, and reduced expression of atopy-
associated genes in infected individuals [31].
However, a study in Ethiopian children showed
a positive association between intestinal infec-
tion with the Trichuris parasite and risk for AD
[51]. This study also showed a history of malaria
to be a predictor of risk for AD [51]. Taken
together, this underscores the need for addi-
tional research. Other hygiene-related factors
associated with increased AD prevalence and
burden include reduced pre- and postnatal
exposure to farm animals and to dogs, antibi-
otic exposure, and reduced diversity of gut flora
[12].
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Climate conditions in Africa and the Middle
East are also likely contributors to the burden of
AD. In Iran and Saudi Arabia, desert conditions
are associated with higher burden of AD because
high temperatures and low humidity exacerbate
dry skin [34, 52]. In Africa, high humidity and
temperature promote growth of allergens,
including mold [31].
QUALITY OF LIFE
Most available data regarding the impact of AD
on patient quality of life (QoL) in the Middle
East is from Saudi Arabia. Numerous studies
have reported that QoL is significantly affected
in Saudi Arabian patients with dermatologic
diseases, including AD [53–56]. Abolfotouh
et al. reported data from 283 adult Saudi Ara-
bian patients with skin disease who completed
the Skindex-16 scale, which assesses QoL across
symptom, emotional, and functional domains
[53]. They used an Arabic version of Skindex-16
adapted for and validated in Saudi Arabian
individuals. The authors found that, of the
eight diagnoses represented among patients,
eczematous dermatitis was associated with the
highest mean symptom domain score, indicat-
ing a high physical burden of disease in patients
with AD [53]. Another study by Ibrahim Al-
Hoqail [54] of adult patients in outpatient der-
matology treatment in Saudi Arabia used an
Arabic version of the Dermatology Life Quality
Index (DLQI), which has shown adequate
Table 2 Environmental risk factors for atopic dermatitis (AD)
Factor Associated effect on AD risk
Urban versus rural
dwelling
Increased risk for AD with urban dwelling [12, 19]
Socioeconomic status Increased risk for allergic sensitization in children with increasing parental socioeconomic
status/goods ownership [38]
Education level of
parents
Increased risk for allergic sensitization and AD in children with increasing parental education level
[38, 51]
Climate Increased risk for AD in colder climates; decreased risk for AD with UV light exposure [12, 19]
Pollution Increased risk for AD with exposure to pollution [12] and with maternal exposure to active or
passive cigarette smoking during prenatal period [39]
Family size Increased risk for AD with smaller family size [19]
Personal hygiene,
sanitation
Increased risk for AD with better personal hygiene in early childhood [40]; increased risk for
allergic sensitization/AD in children with access to sanitation (modern toilets, piped drinking
water) [38, 51]
Antibiotic use Increased risk for AD with antibiotic exposure in prenatal period [39] and during the ﬁrst year of
life [41]; decreased risk with antibiotic exposure after the ﬁrst year of life [39]
Breastfeeding Decreased risk for AD in infants with familial history of AD [19]
Farm and animal
exposure
Decreased risk for AD with frequent prenatal exposure to farm animals; most protective when
compounded with direct exposure [42]; potential decreased risk with postnatal exposure to furry
pets, particularly dogs [39, 43, 44]
Intestinal microﬂora Decreased risk for AD with greater diversity of gut microﬂora in infancy [45]; decreased risk for
allergic sensitization/AD with colonization favoring lactobacilli and biﬁdobacteria in infancy or
childhood [46–49]
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validity and reliability in Moroccan patients
with psoriasis but has not yet been validated for
AD [57, 58]. The DLQI measures the effect of
dermatologic disease on numerous aspects of
daily life, including physical symptoms, feelings
such as embarrassment, activities (social, recre-
ational, work), and personal relationships.
Higher scores are associated with poorer QoL.
The author found that patients with eczema-
tous dermatitis had the third highest mean
DLQI score of eight skin diseases, with only
patients who have papulosquamous disorders
(not otherwise specified by the authors) and
connective tissue/immunological disorders
showing poorer QoL [54]. In another study of
Saudi Arabian adult and teenaged dermatology
outpatients, Ahmed et al. found that most
patients with dermatologic disease (79%) expe-
rienced low QoL, as measured by the DLQI [56].
The most common dermatologic diagnoses
among study patients were acne vulgaris
(29.5%), AD (22.3%), vitiligo (20.7%), and
psoriasis (6.4%).
Additional data indicate that family QoL is
significantly affected when an infant or child
has AD in Saudi Arabia [55, 59, 60]. A study of
the families of 447 Saudi Arabian infants and
children with AD found that only 15 families
(3.4%) had normal QoL; most families (66.4%)
experienced a moderate impact on QoL [60].
The authors measured QoL with an Arabic ver-
sion of the Dermatitis Family Impact Ques-
tionnaire, which they tested for clarity and
feasibility. Results of numerous studies have
shown that degree of impairment in QoL of
Saudi Arabian families is directly proportional
to severity of child disease [55, 59, 60].
QoL data from the remainder of the Middle
East are limited. A study conducted in the
Sanandaj, Kurdistan province of Iran found that
1- to 6-year-old children with severe AD had
significantly lower QoL than the same-age
children with moderate AD [61]. The authors
reported itching/scratching and sleep problems
as the greatest contributors to poor QoL in
patients with severe AD.
QoL data from Africa are limited but have
been reported for South Africa and Uganda. A
2015 South African qualitative study involving
interviews with ten parents of children aged
0–12 years who have AD helped identify detri-
mental physical, emotional, and social effects of
AD to children and families [62]. Consistently
reported factors with prominent impact on
child QoL included physical discomfort from
persistent itching and scratching, low self-
esteem, and social isolation. Parents reported
fatigue owing to care-related loss of sleep and
change in daily routine, as well as emotional
burden, including feelings of frustration, stress,
and confusion. In another study, 81 Ugandan
patients 1.5–75 years of age with pruritus owing
to dermatoses, including AD, were surveyed,
and the QoL of Ugandan patients was compared
with that of German dermatology patients [63].
QoL was measured using a study-specific ques-
tionnaire translated by a physician. Ugandan
patients were more likely than German patients
to experience normal emotional reactions and
were less likely to experience adverse emotional
reactions in the form of aggressive behavior and
loss of drive. The authors reported a trend
toward higher frequency of pruritus affecting
QoL and self-assessment in German patients
than in Ugandan patients. Although this study
did not account for disease severity, results
suggest that the burden of AD on QoL may be
lower in African patients than in European
patients. However, additional research is nec-
essary to make informed comparisons between
African and European or North American
patients.
COMORBIDITIES
In the study measuring QoL of Saudi Arabian
patients with skin diseases, Abolfotouh et al.
found that 31.4% of patients had comorbidities,
the most common being diabetes (43.8%) and
hypertension (47.2%) [53]. About 20% of
patients reported a comorbid psychiatric con-
dition. Numerous additional studies support a
relationship between dermatologic and psychi-
atric conditions in the Middle East. A 2016
study of 254 teenage and adult Saudi Arabian
outpatients with dermatologic conditions,
including AD, reported overall prevalence rates
for depression, anxiety, and stress of 12.6%,
22.1%, and 7.5%, respectively [56]. The
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prevalence rates among the 56 patients with AD
were similar: 10.7% (depression), 21.4% (anxi-
ety), and 7.1% (stress). Dermatology patients
with poor QoL were 3.5 times more likely to
report depression, anxiety, or stress. Women
were nearly three times more likely to report at
least one negative emotional condition than
men, although this was not statistically signifi-
cant. Another study of 875 Saudi Arabian der-
matology patients estimated high overall
prevalence of anxiety (29%) and depression
(14%) [64]. A cross-sectional study of Iranian
dermatology patients reported psychiatric
comorbidities in more than 50% of patients and
showed higher rates of psychiatric comorbidi-
ties in patients with recurrent disease [65].
Collectively, these statistics suggest a poten-
tially alarming pattern of psychological distress
in Middle Eastern patients with dermatological
conditions, including AD.
Although data are limited, comorbidities
have also been noted in African patients. In the
study in which QoL of Ugandan and German
patients with pruritic conditions owing to der-
matoses was compared, depressed mood was
reported in 41% of Ugandan patients (vs 49% of
German patients) [63]. Results of a survey of
Senegalese infants and children with AD
showed that AD significantly increased the risk
for malarial infection in children older than
3.5 years of age and delayed development of
clinical immunity [66].
CURRENT TREATMENT OPTIONS
AND UNMET NEEDS
Although AD treatment guidelines are similar
globally, in managing AD, Africa and the Mid-
dle East face challenges that contribute to dis-
ease burden. In Saudi Arabia, numerous AD
medications are available over the counter, and
medical consultation and treatment are free for
citizens at government hospitals [67]. However,
patients often prefer to see a specialist rather
than a general practitioner, resulting in long
wait lists and potentially delayed diagnosis. A
case report from Saudi Arabia cites use of tradi-
tional medicine, general practitioner non-
adherence to clinical guidelines, and lack of
access to systemic therapies as contributing
factors to disease severity and burden in a
pediatric patient [52]. The author recom-
mended numerous steps to improve local care
for AD in Saudi Arabia, including adequate
refresher training in dermatology for general
practitioners; use of specialized nurses in der-
matology; and enhanced coordination of pri-
mary, secondary, and tertiary care. The report
also emphasized the need for further research
into traditional Middle Eastern medicine and
enhanced regulation of long-term prescription
of potent topical steroids.
A qualitative report of parent impressions of
AD management in the Gauteng district of
South Africa identified dispensation of inap-
propriate medication or insufficient amounts of
medication, inadequate primary care, financial
obstacles, and lack of disease education for
parents and health care providers as unmet
needs in AD treatment [68]. The authors
describe barriers of care general to South Africa.
These include inadequate knowledge of allergic
conditions among primary care providers and
unavailability of treatment. Issues are amplified
in rural settings, where lack of drugs and
equipment, ill-informed health care providers,
and financial obstacles add to the burden of AD.
As in Saudi Arabia, a high proportion of South
African patients report using alternative and
traditional medicine.
AD research and care in Africa might also be
affected by underreporting of the disease,
stemming from limited access to health care
and prioritization of infectious, highly virulent
diseases such as malaria and tuberculosis [31].
Furthermore, many diagnostic tests were
developed for use in European and North
American individuals, and allergens inherent to
tools such as the skin prick test for IgE
immunoreactivity may not be relevant to Afri-
can local environments. In regions with severe
shortages of physicians such as sub-Saharan
Africa, innovative tools to promote access to AD
care such as the African Teledermatology Pro-
ject, which connects sub-Saharan medical
facilities to dermatologists in the USA, Europe,
and Australia, are emerging [69]. However, the
effectiveness of such tools in alleviating AD
burden in Africa requires further research.
232 Dermatol Ther (Heidelb) (2019) 9:223–241
Taking into consideration the unmet needs
of AD patients in Africa and the Middle East, we
outlined treatment recommendations for man-
agement of AD in these patient populations in
Table 3 based on literature [16, 20, 70–93] and
our clinical experience. The goal of treatment
should be threefold: to break the itch–rash cycle
by controlling pruritus, to suppress inflamma-
tion, and to restore skin barrier function. When
colonization or infection occurs, antiseptics,
antibiotics, or antivirals are necessary
[16–18, 20, 21]. The merits and drawbacks of
therapeutic options should be weighed when
developing a treatment plan. Furthermore,
regional differences with respect to affordability
and availability of AD therapies should be con-
sidered as these obstacles have been reported in
Africa [68] and the Middle East [52].
Despite some deviations, our recommenda-
tions largely align with established interna-
tional guidelines and comprise a multifaceted
approach to treatment [16–21]. Emollients and
moisturizers should be treatment mainstays.
Topical corticosteroids are first-line therapies,
but strength and treatment duration should be
considered to avoid adverse events. Calcineurin
inhibitors for AD are an important option,
especially in children and for certain areas such
as the face, neck, and intertriginous areas. Sys-
temic therapies and phototherapy are useful for
moderate to severe cases that remain uncon-
trolled by topical treatments. Behavioral inter-
ventions and disease state education should
also be provided because these interventions
can improve self-management and QoL, pro-
mote optimal sleep and dietary habits, and
reduce physician visits and costs [21, 23].
As new treatments such as topical crisaborole
and the biologic dupilumab become available in
Africa and the Middle East, they should be
added to AD management plans where indi-
cated. However, there is a need for real-world
efficacy, safety, and tolerability data for novel
therapies in Africa and the Middle East because
racial and ethnic differences in genetic and
immune profiles relevant to AD pathophysiol-
ogy have been documented [94, 95] and may
impact treatment response. Furthermore, stud-
ies of the cost-effectiveness of these therapies
will be especially important for regions of low
socioeconomic status.
TREATMENT EFFECT ON QOL
Available information is very limited regarding
the effect of treatment on QoL of patients with
AD in the Middle East and Africa. Results of an
Iranian study showed that 6 weeks of dermato-
logic treatment with ultraviolet light, TCSs, and
topical ointments produced a statistically sig-
nificant improvement in QoL (57% change) as
measured by a Persian version of the DLQI in
patients with chronic dermatitis [96]. Statisti-
cally significant improvement after treatment
was observed for all DLQI subdomains, but the
greatest improvement was seen in the symp-
toms and feelings domain. Results of a study in
Pretoria, South Africa, of 20 infants and chil-
dren with severe AD showed a 33% improve-
ment in mean Parent Index QoL (PIQoL) score
following treatment with pimecrolimus [97].
The PIQoL questionnaire was translated from
English as needed.
CONCLUSIONS
AD is a common, chronic inflammatory skin
disease that is becoming increasingly prevalent
in the developing world. Time trends in Africa
and the Middle East suggest a growing regional
burden of AD. Although data from Africa and
the Middle East are limited, available informa-
tion suggests relatively consistent increases in
prevalence, with particularly large increases in
Africa, and significant impact on QoL. Growing
AD prevalence and burden is a serious public
health problem in Africa and the Middle East
because these regions face unique challenges in
delivering care to patients with AD. Environ-
mental factors contributing to AD prevalence
that are specific to Africa and the Middle East
should be considered for therapeutic strategies,
education, and prevention.
Meaningful understanding of the burden
and treatment of AD in the Middle East and
Africa is impeded by significant gaps in data;
therefore, it requires further investigation. Most
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Table 3 Clinical recommendations for treatment of atopic dermatitis (AD) in Africa and the Middle East
Type of
treatment
Recommendation Merits Drawbacks
Emollients and
moisturizers
• Emollients should be the
mainstay of treatment
• Should be applied at least 5
times/day (acute) or 3
times/day (maintenance)
• Improve skin barrier function
and symptoms [16, 70]
• Reduce need for prescription
anti-inﬂammatory therapies
[16, 71]
• Generally affordable treatment
option [16, 72]
• Insufﬁcient for moderate to
severe cases [16, 18]
• Greasiness/smell of
moisturizer, frequent
application, and adverse
reactions may lead to poor
adherence [72]
• Specialized emollients and
prescription emollient devices
can be costly [16, 20]
Topical
corticosteroids
(TCSs)
• Should be applied 2 times/day
for 7 days (acute); then 1
time/day for 7 days or twice
weekly (maintenance)
• Recommended ﬁrst-line anti-
inﬂammatory therapy
[16, 18–20]
• Effective with satisfactory
safety proﬁle when used as
directed [16, 73, 74]
• Low cost for prescription
therapy with several generic
options [74, 75]
• Potential for long-term local
side effects such as skin
atrophy and systemic side
effects such as HPA axis
suppression merits routine
monitoring [74]
• Limited use in children [74]
• Potential for
hypopigmentation in patients
with skin of color [74]
Topical
calcineurin
inhibitors (TCIs)
• Should be applied 2 times/day
for 1 month (acute); then 2
times/week (maintenance)
• Effective for short- and long-
term treatment of mild to
severe AD in adults and
children [16, 76–79]
• Steroid sparing; reduces need
for TCS when used for long-
term, proactive prevention of
ﬂares [80]
• Useful for sensitive areas (face,
genitals, skin folds) [16, 20]
• Higher cost prescription
therapy [75]
• Local tolerability issues
(stinging/burning) may require
patient counseling to prevent
nonadherence [16, 18]
• Limited in combination with
phototherapy as sun exposure
should be avoided during TCI
treatment [81, 82]
• FDA boxed warning for
cancerogenesis [81, 82]
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Table 3 continued
Type of
treatment
Recommendation Merits Drawbacks
Topical PDE4
inhibitors
• Crisaborole ointment, 2%,
should be applied 2 times/day
• Maintenance algorithm is not
yet deﬁned
• Effective treatment for mild to
moderate AD in children and
adults C 2 years of age [83]
with satisfactory short- and
long-term safety proﬁle
[83, 84]
• Cost-effectiveness
unestablished [85]
• Limited real-word effectiveness,
head-to-head comparative
efﬁcacy, and safety data
available [20]
• Local tolerability events
including application site pain
among most common
treatment-related adverse
events in pivotal [83] and
long-term safety trials [84]
• Currently approved only in
USA [24]
Systemic
therapies
• Sedating antihistamines at
bedtime; nonsedating
antihistamines during the day
if necessary
• Systemic immunosuppressants
(methotrexate, cyclosporine,
azathioprine) or biologics as
second- or third-line therapies
• Antihistamines: widely
available with low side effect
proﬁle (second-generation H1
antagonists) [86]
• Systemic immunosuppressants:
effective in moderate to severe
cases [73, 87, 88]
• Biologics: dupilumab effective
in moderate to severe cases
[89]
• Antihistamines: efﬁcacy in AD
unproven [90], recently
associated with ADHD
symptoms in children with AD
[91]
• Systemic immunosuppressants:
limited long-term use [17, 73];
pronounced side effect proﬁle
necessitates close monitoring
[17, 73]
• Biologics: very cost intensive
[92]; some are investigational
and lack long-term safety and
efﬁcacy data in AD
[17, 18, 21]; dupilumab
approved only in USA [25],
Europe [25], Canada [26], and
Japan [27]
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region-specific data regarding AD in Africa and
the Middle East are concentrated on epidemi-
ology and risk factors associated with AD.
Although many studies have been conducted to
investigate the QoL of dermatology patients in
the Middle East, most are from Saudi Arabia.
Very limited information is available regarding
QoL of patients with AD in Africa and regarding
the effect of treatment on QoL in the Middle
East and Africa. Furthermore, tools to effectively
measure QoL are limited. An Arabic version of
the Skindex-16 has been validated in patients
with inflammatory dermatoses (psoriasis, viti-
ligo, eczematous dermatitis) [98]. Arabic and
Persian versions of the DLQI have been vali-
dated in Moroccan and Iranian dermatology
patients [57, 58, 99]. However, these versions of
the DLQI were not specifically validated in AD
patients, and no information is available
regarding the validity of QoL instruments in
other Middle Eastern ethnicities/cultures or in
Africa. Available data do not adequately address
the economic and academic/occupational
impact of AD in Africa and the Middle East.
There is also a lack of data regarding the region-
specific symptom burden of AD (e.g., pruritus as
a disease burden), which would necessitate tools
such as a standardized itch questionnaire.
Data on treatment options and unmet needs
are limited and are derived primarily from
qualitative case studies and interviews, under-
scoring the need for further research on treat-
ment options and effectiveness in Africa and
the Middle East. These types of data are espe-
cially important because the primary diagnostic
tools and treatments for AD were developed in
European and North American patients. Addi-
tional studies are necessary to better understand
differences in disease presentation in Africa and
the Middle East compared with other regions
and the potential implications of regional phe-
notypic differences on treatment effectiveness.
Our clinical recommendations for improving
management of AD in Africa and the Middle
East outline a multifaceted approach of phar-
macological and nonpharmacological topical
treatments, systemic therapies, phototherapy,
and behavioral interventions.
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Type of
treatment
Recommendation Merits Drawbacks
Other • UV phototherapy if
unresponsive to topical
therapies
• Education regarding
appropriate skin care
• Avoidance of triggers (e.g.,
scented soaps)
• Behavioral modiﬁcations and
patient education: cost
effective with good efﬁcacy
[21, 23]
• UV phototherapy: effective
with good side effect proﬁle
[93]
• UV therapy: high costs
(machine and maintenance)
[20, 93]; requires patient access
to a phototherapy center and
frequent visits [20, 93]; limited
long-term use and use in hairy/
intertriginous areas [93]
ADHD attention deﬁcit hyperactivity disorder, FDA US Food and Drug Administration, HPA hypothalamic-pituitary-
adrenal, PDE4 phosphodiesterase 4
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